Paul Buser retweeted
Our @joyscompounding teachers are Biotech's New Builders, Peter Harwin and Tomas Kiselak of Fairmount Funds Management - PERHAPS THE GREATEST BIOTECH INVESTORS IN THE WORLD TODAY and yet you’ve likely never heard of them. 🧬 🚀
And this is their FIRST EVER INTERVIEW of any kind! 🤫
In just 10 years, they've achieved a net MOIC of well over 20X and net IRR's over 35%. But as you’ll hear on this episode, just HOW they’ve done it is even more wild and inspiring. 🤯 📈
If you are a longtime listener of ours, you know Paul and I are kind of obsessed with the idea of enduring excellence. We’re convinced that to be great and stay great requires constant evolution - a trait not commonly embraced in the investing industry.
When Fairmount began, it looked a lot like other institutional quality biotech hedge funds. Investing mainly in public stocks and perhaps an occasional private crossover investment. But the DREAM was never really about picking stocks. It was always to BUILD great businesses that BUILD great drugs that ultimately improve the quality of life and standard of care for patients.
Against all odds and little external support, they began to experiment, tinkering with licensing and drug development via SPVs until eventually the *distraction became the focus*.
Today, Fairmount has founded 17 companies, with 15 already public translating into a combined market cap of over $50 Billion. In concert with their wholly owned incubator, Paragon Laboratories, Inc., they have developed an incredible 55 drugs with 27 already in the clinic and one receiving FDA approval. Companies like @CogentBio , @dianthustx, @ViridianThera , Oruka Therapeutics, @spyretx and of course Apogee Therapeutics, which was recently acquired by @abbvie for close to $11Billion. And in doing so, they have also accomplished something almost singular as investors, literally building their own opportunity set, with close to 95% of their portfolio now invested in Fairmount-founded companies.
Whether you are a biotech investor or not, there are so many valuable lessons in Peter and Tomas’ journey. I’m just so proud of these guys for all they’ve already accomplished for the benefit of humanity and I feel privileged to call them friends and partners.
Grateful for our sponsors @eightsleep and @portraitanalyst as well as our partners @colossusmag and @patrick_oshag
TIMESTAMPS:
(00:00) Peter Harwin & Tomas Kiselak, Co-Founders at Fairmount Funds
(01:37) The best biotech investors you’ve never heard of
(04:17) Betting on biotech when 85% of drugs fail
(12:28) When waiting felt riskier than starting
(17:15) The vision hidden in Fairmount’s first letter
(24:28) Trying to license a drug with no experience
(27:37) Why you don’t need a PhD to master biotech
(33:11) How Peter found his way into biotech
(37:39) How biotech boomed, crashed and recovered
(46:15) How an idea becomes an approved drug
(53:38) Why a new drug takes a decade and a billion dollars
(56:58) Why drug development is harder than building a skyscraper
(01:01:13) Building their first company on a $500K check
(01:13:54) What building companies taught them as investors
(01:22:45) How Fairmount compounded to $7.5B without new capital
(01:29:49) The biotech playbook built around not failing
(01:36:17) Why the job’s not done
(01:41:07) Paragon, the engine behind Fairmount’s companies
(01:45:35) Finding people who can handle setbacks
(01:49:57) How Fairmount moves faster than the rest of biotech
(01:53:26) How Apogee became an $11B exit
(01:59:19) Why it’s still too soon to call AI in biotech
(02:04:47) What Fairmount’s next 10 years look like
(02:09:10) “Everything starts as nothing”
Paul Buser retweeted
I sat down with Luca Ferrari (@luke10ferrari), Co-Founder & CEO of @bendingspoons, to understand how he’s been building a business designed to compound for decades.
Bending Spoons has a different approach to building companies. Instead of launching products from scratch, it acquires established businesses with product-market fit, integrates them into a shared operating platform, and focuses on making them better.
Luca says the company has grown annualized revenue per Spooner from around $1M to over $4M in roughly three years. Spooners are members of its highly selective core team.
The operating philosophy is just as interesting. Despite managing a growing portfolio of businesses, 99% of decisions are made by the teams running them. Luca believes talent density and extreme ownership beat layers of management, rules, and centralized decision-making.
AI is becoming another major advantage. Bending Spoons uses proprietary technology and internal AI agents to automate analysis, access business data, produce documentation, and help its teams operate with greater autonomy.
Luca believes this could allow the company to grow revenue 10x while increasing headcount by just 3x at most.
We also covered:
- Why Bending Spoons buys product-market fit instead of building from scratch
- How to build a company for 20-30 years instead of chasing a 3-4 year exit
- Why extreme ownership and talent density are the foundation of its culture
- How the company integrates acquisitions without centralizing every decision
- Why proprietary technology takes years to develop and cannot be bought with money
- How AI changes the economics of acquisitions and operating businesses at scale
- Why Luca believes patience and urgency must coexist when building something exceptional
The central idea: Build an exceptional operating platform, acquire great businesses, improve them, and reinvest the cash flow. Then repeat.
TIMESTAMPS:
(00:00) Luca Ferrari, Co-Founder & CEO at Bending Spoons
(00:38) Becoming the best operator in the world
(03:34) From $1M to $4M revenue per Spooner
(06:33) The upside of starting with almost nothing
(11:48) Why copying others leads to mediocre outcomes
(16:53) Building a culture of extreme ownership
(23:03) Is Bending Spoons centralized or decentralized?
(28:48) The AI edge in buying companies
(31:31) Why build when you can buy?
(35:52) Why investors obsess over organic growth
(38:42) Why chasing market trends is a losing game
(44:26) Why Luca would buy shrinking companies forever
(47:27) Beating the law of large numbers
(52:39) How AI is changing the playbook
(57:49) Why AI makes ownership easier, not harder
(01:00:11) “You can’t choose your shareholders ”
(01:02:19) The real reason Bending Spoons went public
(01:04:56) Resetting the bar from Europe
@joyscompounding @RickBuhrmanSGH
Paul Buser retweeted
7/n
$BSP CEO @luke10ferrari on Joys of Compounding @Buhrman_Rick @PaulBuser
Sounds like a very thoughtful operator, not that he needs my opinion
podcasts.apple.com/us/podcas…
Paul Buser retweeted
The benefits of abundant intelligence will accrue far outside of San Fransisco.
Spent the last year writing about capital, sovereignty, and the coming reordering of economic power.
THE COMMANDING HEIGHTS
Commanding-Heights.com
Paul Buser retweeted
The manufacturing accelerator bills itself as "America’s answer to Shenzhen."
spr.ly/6010BHcago
Paul Buser retweeted
Five years ago, Miles Arnone, Will Barker and I started Re:Build because we believed deindustrialization was an economic failure and a national security risk. Today we announced $2.1B in new funding, led by General Catalyst and JPMorganChase’s Strategic Investment Group. Our mission is to ensure the next generation of important products are made, at scale, in America.
$2.1 billion in new capital to ensure the next generation of important products are made, at scale, in America. Led by @generalcatalyst + @jpmorgan. Covered today in @dealbook.
Paul Buser retweeted
$2.1 billion in new capital to ensure the next generation of important products are made, at scale, in America. Led by @generalcatalyst + @jpmorgan. Covered today in @dealbook.
Paul Buser retweeted
Our conversation with A.J. Rohde.
A.J. Rohde is a Senior Partner at Thoma Bravo, the world’s largest software-focused investment firm.
We cover how a tennis background can predict good investors, why the software selloff was really just a duration trade unwinding, and the single number a whole company can rally around.
Enjoy!
TIMESTAMPS
0:00:00 Intro
0:00:34 Why Thoma Bravo Recruits Tennis Players
0:17:16 Drumming as an Outlet
0:26:44 The Spirit of Philadelphia
0:37:08 Buying Licenses for Air
0:48:09 Constants Across Five Decades of Software
1:12:45 Data That Survives Hype Cycles
1:33:15 How Range Makes a Better Investor
Paul Buser retweeted
We are releasing a book today.
Artifacts: A visual history of technology from 1965 to the Present.
59 years. 296 breakthrough moments. 403 images.
A clean chronology of the innovations that built the modern world.
From microprocessors to mobile to AI.
Technology is the greatest story of human optimism.
It is the belief that fragile ideas can become world changing platforms.
Artifacts is that story, in print.
A curated gallery of modern computing that fits on your desk.
Proud to share it.
Link in comments.
Paul Buser retweeted
Nine years ago, I launched Founders (@FoundersPodcast).
Today, I'm launching a new podcast called David Senra.
The first episode goes live this Sunday. Subscribe wherever you watch or listen to podcasts.
Founders will still come out every week.
@scicomm // @hubermanlab
Paul Buser retweeted
Will Thorndike - The Rise of Long Duration, Serial Acquisition Holding Companies
Our @joyscompounding teacher today is Will Thorndike, co-founder of @CompoundingLabs and author of acclaimed book, The Outsiders.
This is one of the most foundational JOC sessions we’ve ever done because of how much Will has shaped our combined teaching and investing vocations. 🥰
The Outsiders is considered one of the most impactful business books of the 21st century. Lauded by @WarrenBuffett and so many others, it profiles eight CEOs who dramatically outperformed their peers by focusing not on charisma and cult of personality attributes, but on the more quiet and unconventional craft of resource allocation—measured, rational, often contrarian decisions that compounded to extraordinary heights over time.
But Will’s influence goes far beyond the page. He is a pioneer in the private equity and search fund worlds, having founded Housatonic Partners in 1994 and also helping originate the modern search fund model—backing early-career CEOs to buy and grow businesses with long time horizons and radically aligned incentives.
Since then, he has invested in the majority of the top 20 search fund outcomes to date, including @Asurion, which he recently profiled on his podcast 50X. You may not have heard about Asurion but it is likely the greatest private equity investment of all time, generating a more than 5,000 times multiple on invested capital. 🤯
In more recent years, Will’s taken the best of what he’s learned from the PE and Search worlds and is now developing what we think may be an ENTIRELY NEW ASSET CLASS - long-duration, serial acquisition holding companies.
Here are some of the structural and operational features of these businesses:
- These are newco formations that are effectively capitalized on day 1 at book value
- They focus on buying & building recurring revenue businesses in niche markets
- Radical equity efficiency - with often just $10 - 25 million of equity capital deployed forever
- An ethos of exceptional resource allocation → very much aligned with the Outsiders playbook
- The harnessing of both organic AND inorganic growth with a focus on improvability with the assets they acquire
- And, very importantly, these are investors backing founders with an unlimited time horizon and with a focus on ‘multiple on invested capital’ rather than IRR
The alchemy of these attributes are companies that don’t exist to be sold but rather to eternally flourish ♾ – an asset class that harnesses the joys of compounding better than anything else we’ve come across. 📈
I hope you enjoy this class on the rise of long duration, serial acquisition holding companies with our friend and mentor, the eternal outsider, Will Thorndike!
Links in comments.
Paul Buser retweeted
We made it! #Omaha ☘️⚾️

















